Credit Suisse Group AG reiterated their buy rating on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in a report issued on Wednesday morning. The firm currently has a $101.00 target price on the biopharmaceutical company’s stock.

A number of other research firms have also commented on RARE. Morgan Stanley restated a hold rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. Jefferies Group set a $109.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a buy rating in a research report on Monday, September 12th. JMP Securities restated a buy rating and issued a $84.00 price objective (up from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. JPMorgan Chase & Co. set a $110.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a buy rating in a research report on Monday, August 8th. Finally, Piper Jaffray Cos. set a $82.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a buy rating in a research report on Tuesday, August 9th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Ultragenyx Pharmaceutical currently has an average rating of Buy and a consensus target price of $97.32.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 76.58 on Wednesday. The firm has a 50-day moving average of $67.24 and a 200 day moving average of $62.97. The firm’s market capitalization is $3.02 billion. Ultragenyx Pharmaceutical has a 12 month low of $46.52 and a 12 month high of $117.12.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.46) EPS for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.02. During the same quarter in the prior year, the company posted ($0.83) EPS. Equities research analysts forecast that Ultragenyx Pharmaceutical will post ($5.93) earnings per share for the current year.

In related news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, July 15th. The shares were sold at an average price of $50.85, for a total value of $1,017,000.00. Following the transaction, the chief executive officer now directly owns 513,597 shares of the company’s stock, valued at $26,116,407.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sunil Agarwal sold 649 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $52.68, for a total transaction of $34,189.32. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $100,000. DIAM Co. Ltd. purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $177,000. Springbok Capital Management LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the first quarter valued at approximately $189,000. BlackRock Inc. increased its position in shares of Ultragenyx Pharmaceutical by 58.5% in the second quarter. BlackRock Inc. now owns 3,973 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,467 shares during the last quarter. Finally, Creative Planning increased its position in shares of Ultragenyx Pharmaceutical by 16,700.0% in the second quarter. Creative Planning now owns 4,200 shares of the biopharmaceutical company’s stock valued at $205,000 after buying an additional 4,175 shares during the last quarter. 93.06% of the stock is currently owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.